Roivant Sciences Stock Surges 17%, With A 11-Day Winning Spree
Roivant Sciences (ROIV) stock hit day 11 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 17% return. The company has gained about $1.9 Bil in value over the last 11 days, with its current market capitalization at about $13 Bil. The stock remains 59.0% above its value at the end of 2024. This compares with year-to-date returns of 16.9% for the S&P 500.
ROIV is a biopharmaceutical and healthcare technology company that researches and develops medicines, founded in 2014 and based in London. After this rally, is ROIV still a buy – or is it time to lock in gains? Deep dive with Buy or Sell ROIV.
A single stock can be risky, but there is a huge value to a broader, diversified approach we take with the Trefis High Quality Portfolio. We go beyond just equities. Is a portfolio of 10% commodities, 10% gold, and 2% crypto in addition to equities and bonds likely to return more during the next 1-3 years, and protect you better if markets crash 20%? We have crunched the numbers.
Comparing ROIV Stock Returns With The S&P 500
The following table summarizes the return for ROIV stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | ROIV | S&P 500 |
|---|---|---|
| 1D | 3.2% | 1.2% |
| 11D (Current Streak) | 17.3% | 4.9% |
| 1M (21D) | 24.0% | 3.5% |
| 3M (63D) | 64.7% | 7.9% |
| YTD 2025 | 59.0% | 16.9% |
| 2024 | 5.3% | 23.3% |
| 2023 | 40.6% | 24.2% |
| 2022 | -20.7% | -19.4% |
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades. However, big gains can follow sharp reversals – but how has ROIV behaved after prior drops? See ROIV Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 105 S&P constituents with 3 days or more of consecutive gains and 40 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 80 | 22 |
| 4D | 13 | 13 |
| 5D | 3 | 3 |
| 6D | 2 | 2 |
| 7D or more | 7 | 0 |
| Total >=3 D | 105 | 40 |
Key Financials for Roivant Sciences (ROIV)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $32.7 Mil | $29.1 Mil |
| Operating Income | $-824.9 Mil | $-1.1 Bil |
| Net Income | $4.3 Bil | $-172.0 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ4 | 2026 FQ1 |
|---|---|---|
| Revenues | $7.6 Mil | $2.2 Mil |
| Operating Income | $-285.0 Mil | $-284.9 Mil |
| Net Income | $-206.5 Mil | $-223.4 Mil |
While ROIV stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.